Novo Nordisk A/S logo
Novo Nordisk A/S (NVO)
Compare

Novo Nordisk A/S (NVO) paid $1.80 in dividends per share over the trailing twelve months. The 5-year dividend CAGR is +10.58%.

NVO Annual Dividends per Share (Dividend History)

This step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency (typically quarterly or semi-annually).

Annual Dividend History List

Payment DateNominal Dividend / ShareDistribution Change
Mar 30, 2026$1.22+108.34% Hike
Aug 18, 2025$0.58-48.86% Cut
Mar 31, 2025$1.14+121.04% Hike
Aug 16, 2024$0.52-44.38% Cut
Mar 22, 2024$0.93+112.09% Hike
Aug 18, 2023$0.44-25.77% Cut
Mar 24, 2023$0.59+104.34% Hike
Aug 12, 2022$0.29-43.49% Cut
Mar 25, 2022$0.51+85.80% Hike
Aug 16, 2021$0.28-40.32% Cut
Mar 26, 2021$0.46+78.09% Hike
Aug 14, 2020$0.26-33.84% Cut
Mar 27, 2020$0.39+74.13% Hike
Aug 16, 2019$0.22-42.16% Cut
Mar 22, 2019$0.39+68.07% Hike
Aug 17, 2018$0.23-42.64% Cut
Mar 23, 2018$0.40+70.10% Hike
Aug 17, 2017$0.24-29.32% Cut
Mar 23, 2017$0.34+47.83% Hike
Aug 11, 2016$0.23-52.67% Cut
Mar 18, 2016$0.48+31.26% Hike
Mar 19, 2015$0.36-12.08% Cut
Mar 21, 2014$0.42+33.84% Hike
Mar 21, 2013$0.31+23.60% Hike
Mar 22, 2012$0.25+33.06% Hike
Mar 24, 2011$0.19+38.76% Hike
Mar 25, 2010$0.14+25.21% Hike
Mar 19, 2009$0.11+15.20% Hike
Mar 13, 2008$0.09+52.16% Hike
Mar 8, 2007$0.06+28.92% Hike
Mar 9, 2006$0.05+12.07% Hike
Mar 10, 2005$0.04+18.48% Hike
Mar 17, 2004$0.04+38.38% Hike
Mar 26, 2003$0.03+32.17% Hike
Mar 13, 2002$0.02+25.35% Hike
Mar 21, 2001$0.02+26.65% Hike
Mar 24, 2000$0.01+11.73% Hike
Mar 25, 1999$0.01+82.76% Hike
Mar 27, 1998$0.01+7.39% Hike
Apr 25, 1997$0.01+33.69% Hike
May 1, 1996$0.00+9.88% Hike
Apr 24, 1995$0.00+46.52% Hike
Apr 26, 1994$0.00-4.90% Cut
Apr 22, 1993$0.00+3.56% Hike
Apr 28, 1992$0.00-10.64% Cut
Apr 19, 1991$0.00-3.80% Cut
Apr 23, 1990$0.00+34.69% Hike
Apr 21, 1989$0.00-11.29% Cut
Apr 21, 1988$0.00+26.06% Hike
Apr 20, 1987$0.00-15.76% Cut
Apr 21, 1986$0.00+32.82% Hike
Apr 19, 1985$0.00

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Bagsvaerd
77,406 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar